Login to Your Account

Clinic Roundup

Tuesday, July 19, 2011
Merck & Co. Inc., of Whitehouse Station, N.J., reported final results from a Phase II study, extending out to 240 weeks, of its integrase inhibitor Isentress (raltegravir) in combination therapy in treatment-naive adult HIV-1-infected patients.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription